Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CAO Robert F. Werner sold 226 shares of the business's stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $11,910.20. Following the completion of the sale, the chief accounting officer now directly owns 53,043 shares in the company, valued at approximately $2,795,366.10. This trade represents a 0.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Twist Bioscience Price Performance
Shares of NASDAQ:TWST opened at $51.56 on Wednesday. Twist Bioscience Co. has a one year low of $26.51 and a one year high of $60.90. The firm has a market capitalization of $3.06 billion, a price-to-earnings ratio of -14.32 and a beta of 1.82. The company's fifty day moving average price is $44.65 and its 200-day moving average price is $46.58.
Analyst Ratings Changes
A number of research firms recently weighed in on TWST. Evercore ISI upped their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Robert W. Baird upped their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a report on Tuesday, November 19th. Leerink Partners upped their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. Barclays decreased their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a report on Tuesday, November 19th. Finally, Scotiabank increased their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus target price of $51.00.
⭕ [URGENT] Buy Alert just triggered
From Behind the Markets | Ad
My absolute favorite stock just hit a critical "buy now" trigger price.
Click here for the ticker >>>
Check Out Our Latest Stock Report on TWST
Institutional Investors Weigh In On Twist Bioscience
A number of institutional investors have recently made changes to their positions in TWST. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience in the 3rd quarter valued at $43,992,000. Point72 Asset Management L.P. boosted its position in Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company's stock valued at $33,168,000 after buying an additional 613,057 shares during the period. Fred Alger Management LLC boosted its position in Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company's stock valued at $32,272,000 after buying an additional 575,080 shares during the period. State Street Corp boosted its position in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after buying an additional 526,028 shares during the period. Finally, Wellington Management Group LLP boosted its position in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock valued at $36,042,000 after buying an additional 521,272 shares during the period.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
